8 completed. 4 Phase 3, 2 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow Parke-Davis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia YM087 oral - Hyponatremia | Phase 3 | Completed | Cumberland Pharmaceuticals | 83 | 2000-01-01 | 2014-05-02 |
| Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study 1/10 NA/EE, Placebo - Myocardial Ischemia | Not applicable | Completed | Cedars-Sinai Medical Center | 37 | 1999-12-01 | 2019-04-24 |
| Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly. Carbamazepine, Gabapentin, Lamotrigine - Seizures | Phase 3 | Completed | US Department of Veterans Affairs | 720 | 1998-01-01 | 2023-10-30 |
| CI-994 in Treating Patients With Advanced Myeloma CI-994 - Multiple Myeloma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 6 | 1997-08-01 | 2012-09-25 |
| TART - Troglitazone Atherosclerosis Regression Trial troglitazone - Atherosclerosis, Diabetes Mellitus | Phase 2 / Phase 3 | Completed | Parke-Davis | 288 | 1997-01-01 | 2009-12-11 |
| The VA HDL Intervention Trial (HIT): Secondary Prevention of Coronary Heart Disease in Men With Low HDL-Cholesterol and Desirable LDL-Cholesterol gemfibrozil, Placebo - Coronary Heart Disease | Phase 3 | Completed | VA Office of Research and Development | 2531 | 1991-06-01 | 2015-10-21 |
| A Study of CI-1012 in HIV-Infected Patients CI-1012 - HIV Infections | Phase 1 | Completed | Parke-Davis | 32 | 2005-06-24 | |
| A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients CI-1012 - HIV Infections | Phase 1 | Completed | Parke-Davis | 40 | 2005-06-24 |
HIV Infections (2) · Atherosclerosis (1) · Cardiovascular Diseases (1) · Coronary Disease (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Hyponatremia (1) · Insulin Resistance (1) · Multiple Myeloma (1) · Myocardial Ischemia (1) · Neoplasms, Plasma Cell (1) · Seizures (1)
Carbamazepine (1) · Gabapentin (1) · Gemfibrozil (1) · Histone Deacetylase Inhibitors (1) · Lamotrigine (1) · Troglitazone (1) · conivaptan (1) · tacedinaline (1)
United States (7) · Belgium (1) · Finland (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Poland (1) · Spain (1) · United Kingdom (1)
Art Wheeler, MD (1) · C. Noel Bairey Merz, MD (1) · Carl Pepine, MD (1) · Connie McLaughlin, PharmD (1) · George Sopko, MD (1) · Hanna E. Bloomfield, MD MPH (1) · Howard N. Hodis, MD (1) · James Symons, PhD (1) · Melissa Alsina, M.D. (1) · Nathaniel Reichek, MD (1) · Robert B Weiss, MD (1) · Sheryl Kelsey, PhD (1) · Steve Reis, MD (1) · Vijay Misra, MD (1) · William Rogers, MD (1)
PMID 10438259, PMID 12117397, PMID 12117730, PMID 12456232, PMID 20569710, PMID 8806347, PMID 9778079